Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

William D. Tap, MD
Published: Friday, Jun 05, 2015



William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Soft tissue sarcomas are a rare and heterogeneous group of malignancies where there have not been tremendous advances, says Tap. In a randomized phase Ib/II study olaratumab, a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, was evaluated with or without doxorubicin. The results were significant, says Tap, with the combination showing a 10-month improvement in overall survival compared to doxorubicin alone in soft tissue sarcoma patients.

Based on these results, olaratumab received breakthrough designation status from the FDA and a large phase III study will now be conducted, says Tap.
 


William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Soft tissue sarcomas are a rare and heterogeneous group of malignancies where there have not been tremendous advances, says Tap. In a randomized phase Ib/II study olaratumab, a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, was evaluated with or without doxorubicin. The results were significant, says Tap, with the combination showing a 10-month improvement in overall survival compared to doxorubicin alone in soft tissue sarcoma patients.

Based on these results, olaratumab received breakthrough designation status from the FDA and a large phase III study will now be conducted, says Tap.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x